Log in to your Inderes Free account to see all free content on this page.
BioArctic
173
SEK
+14.27 %
BIOA B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
7 following
www.bioarctic.se/en
BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.
Revenue
616M
EBIT %
41.01 %
P/E
66.54
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BIOA B
Daily low / high price
146 / 173.9
SEK
Market cap
15.29B SEK
Turnover
80.96M SEK
Volume
507K
Latest videos
Financial calendar
Interim report
14.11.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Lars Lannfelt | 33.4 % | 49.2 % |
Pär Gellerfors | 21.6 % | 32.6 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BioArctic, Audiocast with teleconference, Q3'24
BioArctic: Interim Report for the period July - September 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio